Clinical Trial Update: A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]

View source ↗

Summary

This document reports on a Phase 3 trial of epcoritamab versus investigator's choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING